John N. Wang

John N. Wang

Auto-generated profile, based on publicly available information

John N. Wang

Arc Institute, Palo Alto, CA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in bioRxiv
Verified
Preprint
Open access
LFLuis Santiago Mille Fragoso
Luis Santiago Mille Fragoso
CDClaudia L. Driscoll
Claudia L. Driscoll
JWJohn N. Wang
John N. Wang
HDHaoyu Dai
Haoyu Dai
TWTalal Widatalla
Talal Widatalla
XGXiaojing J. Gao
Xiaojing J. Gao
Obtaining novel antibodies against specific protein targets is a widely important yet experimentally laborious process. Meanwhile, computational methods for antibody design have been limited by low success rates that currently require resource-intensive screening. Here, we introduce Germinal, a broadly enabling generative pipeline that designs antibodies against specific epitopes with nanomolar binding affinities while requiring only low-n experimental testing. Our method co-optimizes antibody structure and sequence by integrating a structure predictor with an antibody-specific protein language model to perform de novo design of functional complementarity-determining regions (CDRs) onto a user-specified structural framework. When tested against four diverse protein targets, Germinal successfully designed functional antibodies across all targets and binder formats, testing only 43-101 designs for each antigen. Validated designs also exhibited robust expression in mammalian cells and high sequence and structural novelty. We provide open-source code and full computational and experimental protocols to facilitate wide adoption. Germinal represents a milestone in efficient, epitope-targeted de novo antibody design, with notable implications for the development of molecular tools and therapeutics.